9j6w

Publication Abstract from PubMed

Metformin is the only antihyperglycemic biguanide targeting type 2 diabetes mellitus with proven safety. Although a mechanism of action involving tight inhibition of the respiratory complex I has been proposed for hydrophobic biguanides, it remains elusive for the hydrophilic metformin, whose excellent pharmacological tolerance depends on weak complex I inhibition without competitive nature. Here we solved cryo-electron microscopy structures of the metformin-bound porcine respirasome. Our structural and kinetic data are consistent with a model in which metformin enters complex I only in its open state and becomes trapped at the ubiquinone redox site by ubiquinone-induced conformational closing of the enzyme. By contrast, the hydrophobic proguanil alone occupies both the entrance and the redox site of the ubiquinone channel in open and closed complex I and is kinetically consistent with competitive inhibition with conformation-dependent affinities. Our data provide the molecular basis for metformin's well-known superior properties, such as a wide therapeutic window and positive ubiquinone cooperativity, leading to its clinical success and facilitating future therapeutic developments.

Hydrophilic metformin and hydrophobic biguanides inhibit mitochondrial complex I by distinct mechanisms.,He Z, Teng F, Yang Y, Guo R, Wu M, Han F, Tian H, Wang J, Hu Y, Jiang Y, Zhang L, Xu C, Yang F, Zhou J, Zhang S, Letts JA, Zhou R, Zhou L Nat Struct Mol Biol. 2025 Nov 10. doi: 10.1038/s41594-025-01710-6. PMID:41214295^[1]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.